Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DCF Valuation
Base-case fair value
€131.49
Intrinsic €175.33 · 25% MOS
Current price: €69.15
Base-case summary
Our base-case DCF for Pharma Mar, S.A. (PHM.XMAD) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 26.4% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from €58M in trailing free cash flow, this produces an intrinsic value of €175.33 per share. A 25% safety margin gives a fair value of €131.49, suggesting the stock is currently 90% undervalued against the €69.15 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
€58M
Cash & equivalents
€167M
Total debt
€49M
Shares outstanding
17M